 CARMIEL, Israel, Aug. 13, 2021 PRNewswire -- Protalix BioTherapeutics, Inc. NYSE American: PLX TASE: PLX, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today announced the entry into definitive agreements the Exchange Agreements relating to exchanges the Exchanges of an aggregate of 54.65 million principal amount of the Companys outstanding 7.50 Senior Secured Convertible Notes due 2021 the Existing Notes for an aggregate of 28.75 million principal amount of newly issued 7.50 Senior Secured Convertible Notes due 2024 the Exchange Notes, 25.90 million in cash, and accrued and unpaid interest through the closing date. The Exchanges are expected to close as soon as practicable, subject to satisfaction of certain closing conditions. 